Imugene Limited

Company Profile

Imugene Limited had its IPO on under the ticker symbol IUGNF.

The company operates in the Healthcare sector and Biotechnology industry. Imugene Limited has a staff strength of 0 employees.

Stock update

Shares of Imugene Limited opened at $0.04 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.04 - $0.04, and closed at $0.04.

This is a +8.64% increase from the previous day's closing price.

A total volume of 102,296 shares were traded at the close of the day’s session.

In the last one week, shares of Imugene Limited have slipped by -5.17%.

Imugene Limited's Key Ratios

Imugene Limited has a market cap of $292.64 million, indicating a price to book ratio of 8.5063 and a price to sales ratio of 61.8412.

In the last 12-months Imugene Limited’s revenue was $10.52 million with a gross profit of $10.52 million and an EBITDA of $-38520656. The EBITDA ratio measures Imugene Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Imugene Limited’s operating margin was -387.51% while its return on assets stood at -14.84% with a return of equity of -23.95%.

In Q2, Imugene Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 25.1%.

Imugene Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Imugene Limited’s profitability.

Imugene Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -19.6436. Its price to sales ratio in the trailing 12-months stood at 61.8412.

Imugene Limited stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$195.81 million

Total Liabilities

$6.08 million

Operating Cash Flow

$-159464.00

Capital Expenditure

$125229

Dividend Payout Ratio

0%

Imugene Limited ended 2024 with $195.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $195.81 million while shareholder equity stood at $188.37 million.

Imugene Limited ended 2024 with $0 in deferred long-term liabilities, $6.08 million in other current liabilities, in common stock, $-142692195.00 in retained earnings and $0 in goodwill. Its cash balance stood at $153.15 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Imugene Limited’s total current assets stands at $164.40 million while long-term investments were $217564.00 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.34 million and inventory worth $0.

In 2024, Imugene Limited's operating cash flow was $-159464.00 while its capital expenditure stood at $125229.

Comparatively, Imugene Limited paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.04

52-Week High

$0.18

52-Week Low

$0.04

Analyst Target Price

$

Imugene Limited stock is currently trading at $0.04 per share. It touched a 52-week high of $0.18 and a 52-week low of $0.18. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.06 and 200-day moving average was $0.09 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1477.9% of the company’s stock are held by insiders while 915.2% are held by institutions.